Signals, Powered By EquityPandit
Cadila Healthcare has received final approval from USFDA, to market Tizanidine tablets USP in strengths of 2 mg and 4 mg.
The tablets will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahemdabad and it is used for treating muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles.
Moreover, the group now has more than 180 approvals and has filed over 320 ANDAs since the starting of filing process in FY 2003-04.
